Carisma Therapeutics Inc.

Regulatory Filings • Dec 29, 2025

15-12G 1 tm2534191d1_1512g.htm 15-12G

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 001-36296

CARISMA THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Carisma Therapeutics Inc.

3675 Market Street, Suite 401

Philadelphia, PA 19104

(267) 491-6422

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, $0.001 par value

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	x
Rule 12g-4(a)(2)	¨
Rule 12h-3(b)(1)(i)	x
Rule 12h-3(b)(1)(ii)	¨
Rule 15d-6	¨
Rule 15d-22(b)	¨

Approximate number of holders of record as of the certification or notice date: 36

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Pursuant to the requirements of the Securities Exchange Act of 1934, Carisma Therapeutics Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: December 29, 2025
By:	/s/ Steven Kelly
Name:	Steven Kelly
Title:	Interim Chief Executive Officer

Field: Page; Sequence: 2; Options: Last

Field: /Page